[Development of an anti-HIV gene therapy based on the antiviral properties of beta interferon].
The aim of our work is to explore the use of IFN-beta for gene therapy in the HIV-infection. Transduction of various HIV target cells with a retroviral vector that carries the Hu-IFN-beta coding sequence under constitutive low expression control, confers resistance to HIV without affecting cell replication or function. After transduction, lymphocytes from HIV-infected patients develop resistance to the endogenous virus, provided the cells are derived from individuals with a CD4 cell count higher than 200 per mm3.
De Maeyer
E
E
UMR 177 du CNRS, Institut Curie, Centre Universitaire, Orsay.
Vieillard
V
V
Cremer
I
I
Rousseau
V
V
Jacomet
C
C
Debré
P
P
Rozenbaum
W
W
Autran
B
B
Lauret
E
E
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage / Q000235:genetics* / Q000627:therapeutic use; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology; D012190:Retroviridae; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D016899:Interferon-beta